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ABSTRACT
Objective To assess the effect of a multimodal group
exercise intervention, as an adjunct to conventional care,
on fatigue, physical capacity, general wellbeing, physical
activity, and quality of life in patients with cancer who
were undergoing adjuvant chemotherapy or treatment for
advanced disease.
Design Randomised controlled trial.
Setting Two university hospitals in Copenhagen,
Denmark.
Participants 269 patients with cancer; 73 men, 196
women,meanage47years(range20-65)representing21
diagnoses. Main exclusion criteria were brain or bone
metastases. 235 patients completed follow-up.
Intervention Supervised exercise comprising high
intensity cardiovascular and resistance training,
relaxation and body awareness training, massage, nine
hours weekly for six weeks in addition to conventional
care, compared with conventional care.
Main outcome measures European Organization for
Research and Treatment of Cancer Quality of Life
Questionnaire (EORTC QLQ-C30), Medical Outcomes
Study Short Form (MOS SF-36), Leisure Time Physical
Activity Questionnaire, muscular strength (one repetition
maximum), maximum oxygen consumption (Vo2max).
Statistical methods The general linear model was used
for continuous outcome while analysis of associates
betweencategoricaloutcomeswasperformedasanalysis
of marginal homogeneity in contingency tables.
Results Adjusted for baseline score, disease, and
demographic covariates, the intervention group showed
an estimated improvement at six weeks for the primary
outcome,fatigue,of−6.6points(95%confidenceinterval
−12.3 to −0.9, P=0.02; effect size=0.33, 0.04 to 0.61).
Significant effects were seen on vitality (effect size 0.55,
95% CI 0.27 to 0.82), physical functioning (0.37, 0.09 to
0.65), role physical (0.37, 0.10 to 0.64), role emotional
(0.32, 0.05 to 0.59), and mental health (0.28, 0.02 to
0.56) scores. Improvement was noted in physical
capacity: estimated mean difference between groups for
maximum oxygen consumption was 0.16 l/min (95% CI
0.1to0.2,P<0.0001)andformuscularstrength(legpress)
was29.7kg(23.4to34.9,P<0.0001).Nosignificanteffect
was seen on global health status/quality of life.
Conclusion A supervised multimodal exercise
interventionincludinghighandlowintensitycomponents
was feasible and could safely be used in patients with
various cancers who were receiving adjuvant
chemotherapy or treatment for advanced disease. The
intervention reduced fatigue and improved vitality,
aerobic capacity, muscular strength, and physical and
functional activity, and emotional wellbeing, but not
quality of life.
Trial registration Current Controlled trials
ISRCTN05322922.
INTRODUCTION
An increasing number of patients with cancer are
offered chemotherapy given either alone or in combi-
nation with radiotherapy, surgery, or both as neoadju-
vant, concomitant, or adjuvant treatment. Improved
treatments have resulted in prolonged survival and
better control of disease and treatment related compli-
cations. The majority of patients will, however, still
face a range of symptoms and side effects such as nau-
sea, vomiting, pain, insomnia, appetite loss, and fati-
gue. Surveys have shown that fatigue is among the
most frequent and burdensome side effect of che-
motherapy and results in impaired or diminished phy-
sical activity.
1 Whereas most side effects are drug
specific, fatigue is associated not only with most anti-
neoplastic drugs but also with the disease itself.
2 Pre-
vention and treatment of fatigue are complicated;
treatment with drugs alone is rarely adequate. In addi-
tion, psychosocial problems often follow the diagnosis
of cancer and subsequent chemotherapy.
3 For some
patients, diagnosis and treatment are synonymous
with an inactive daily life,
4 resulting in loss of muscle
mass and strength.
56Exercise training has been intro-
duced to improve physical capacity and quality of life
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BMJ | ONLINE FIRST | bmj.com page 1 of 11and to reduce fatigue. Few intervention studies have
includedpatientswhowereundergoingchemotherapy
and the evidence is modest.
7-9
Exercise studies have included predominantly
women with breast cancer after cytostatic treatment
and the interventions provided improved physical fit-
ness and psychological benefits.
7-9 Typically studies
investigated the effects of a single activity of moderate
intensity, such as cardiovascular training on stationary
bicycles, rather than resistance training. Additional
studies are needed to provide evidence on whether
patients with different cancer diagnoses, stages of dis-
ease, and symptoms can benefit from combined resis-
tance and cardiovascular training when undergoing
chemotherapy. Moreover, high intensity exercise
might further improve the patients’ physical capacity,
as recorded in sports science studies including healthy
adults.
510
Awiderangeoflowintensityinterventionscompris-
ingpsychosocialactivities(relaxationandmassage)are
recommended as adjuvants to pharmacological thera-
pies,torelievenausea,pain,andfatigueandtoincrease
the patient’s perception of self control.
1112
This body of research provides evidence that exer-
ciseandpsychosocialinterventionsmightbebeneficial
when tested as separate components. We developed a
multimodal intervention consisting of high and low
intensity components to achieve a broad spectrum of
effects. The intervention was designed to appeal to
male and female patients with cancer, irrespective of
diagnosis and stage of disease.
The objective of the present study was to investigate
the effect of a six week supervised structured group
intervention comprising high intensity physical train-
ing and low intensity training in an intervention group
comparedwith a controlgroup. We tested the hypoth-
esisthattheintervention,asanadjuncttoconventional
care, could reduce fatigue (primary outcome), and
improve other side effects, general physical and emo-
tional wellbeing, global health status or quality of life,
physical capacity, and physical activity in men and
women with cancer who were undergoing adjuvant
chemotherapy or treatment for advanced disease.
METHODS
Recruitment and assignment
Participants were recruited from the departments of
oncology and haematology at Rigshospitalet and Her-
lev Hospital (Copenhagen University Hospitals) from
March 2004 to March 2007. Participants were eligible
if they had a diagnosis of cancer, had received at least
one cycle of chemotherapy for advanced disease or as
adjuvanttreatment,hadaWHOperformancestatusof
0 or 1, and were aged 18-65 years. Exclusion criteria
were brain or bone metastases, thrombocytopenia
(<50×10
9/l), myocardial infarction within the past
three months, or uncontrolled hypertension (diastolic
pressure >95 mm Hg). The patients were approached
and enrolled by research nurses or by physicians and
nurses from eight treatment departments. Further-
more, the participants could contact the project team
directly; information was accessible on posters and
pamphlets in the hospitals’ inpatient and outpatient
departments.
After written informed consent, the baseline mea-
sures were obtained from the participants, who were
randomly allocated to an intervention or a control
group. The patients were stratified by sex, diagnosis
category (breast, bowel, other oncological malignan-
cies, haematological malignancies), and disease status
(noevidenceofdiseaseorevidenceofdisease).Patients
with no evidence of disease received adjuvant treat-
ment after radical local treatment for their cancer dis-
ease, while patients with evidence of disease had
residual or advanced disease after the initial diagnosis
of cancer was made by biopsy or local treatment. Ran-
domisation was done by computer (Clinical Internet
Trial Management System: CITMAS). The allocation
sequence was executed by the clinical research unit
and concealed from the project team. The data were
collected by a physiotherapist and a trained nurse spe-
cialist, who also conducted the daily training sessions.
Data were anonymised by use of an identification
code; administrative data were kept in a separate data-
base. Blinding the participants to group assignment
was not possible. Outcome measures were keyed in
and analysed by research assistants who were not
involved with the participants.
Intervention: exercise programme
Participants assigned to the intervention group
received standard medical care while participating in
agroupbasedmultimodalhighandlowintensityexer-
cise intervention (supervised by trained nurse specia-
lists and physiotherapists). There were seven to 10
participants per group, each group including indivi-
dualsofbothsexesandwithvariousdiagnosesanddis-
ease statuses.
On Mondays, Wednesdays, and Fridays, the
patientsparticipated in highintensity physicaltraining
for90minutesfollowedby30minutesrelaxationtrain-
ing.OnTuesdaystheprogrammeincluded90minutes
of body awareness training followed by 30 minutes of
relaxation training. Mondays and Fridays were
reserved for the patients to receive 30 minutes of mas-
sage. The intervention took place in a fitness facility at
Rigshospitalet, and was undertaken over a six week
period for nine hours per week. The multimodalinter-
vention constituted a total package; the participants
could not select one activity in preference over
another. The intervention consisted of high and low
intensity activities equivalent to a total of 43 metabolic
equivalent of task (MET) hours per week.
13 The high
intensity physical training sessions comprised three
components: 30 minutes of warm-up exercises,
45 minutes of resistance training, and 15 minutes of
cardiovascular training. The warm-up consisted of
dynamic exercises with the large muscle groups,
along with balance and coordination training, and
had an estimated average intensity of 9 METs (4.5
MET hours per training session). Six machines were
used for resistance training: a leg press, a chest press,
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knee extension (Technogym, Gambettola, Italy). The
one repetition maximum test was used to measure the
weight a patient could lift once on any specific
machine. The weight was expressed as 100% of the
patient’s strength and a training programme was then
developedbasedonthatmeasure.Theaimoftheresis-
tance training component was to accomplish three
continuous series of five to eight repetitions at 70-
100% of the one repetition maximum test.
14 To ensure
progression, all patients performed one repetition
maximum test every other week, with subsequent
adjustmentsmadetotheirtrainingprogrammes.Resis-
tance trainingwasestimated to have an intensity of5.5
METs (4 MET hours per training session). Cardio-
vascular training involved interval training on station-
ary bicycles with a workload of 70-250 W, equivalent
to 85-95% of each participant’s maximum heart rate.
This training was estimated to have an intensity of 15
METs (3.75 MET hours per training session).
Lowintensityphysicaltrainingcomprisedthreepsy-
chosocial components: relaxation (30 minutes four
timesaweek),bodyawarenessandrestorativetraining
(90minutesonceaweek),andmassage(30mintwicea
week). In relaxation sessions, the participants lay on
mats with pillows and blankets and were instructed in
the use of relaxation mechanisms, using principles of
progressive muscle relaxation. Participants were
instructed in tensing and relaxing major muscle
groups, working from head to foot.
15 They were
asked to focus on the contrast in sensations between
muscle tension and relaxation. Audiotape progressive
muscle relaxation was used to enhance treatment
integritybyassuringthatall participantswereexposed
to the same instructions. Body awareness and restora-
tive training adopted various themes that focused on
the participants’ awareness, recognition, and control
of their bodies. The first session was dedicated to
stretching, which can contribute to reducing discom-
fort and pain.
16 The theme selected for weeks 2 and 3
was respiration, inspired by yoga, which aims to
increase mental and physical energy.
17 The remaining
weeks (weeks 4-6) focused on postural awareness and
movementre-education,basedonPilatestechniques.
18
Massage was relaxing, facilitative, or therapeutic,
includingscartissuemassage.Afewpatientsrequested
venous pump massage or ultrasound therapy.
19
Relaxation training and massage were each estimated
tohaveanintensityof1MET(totalof3METhoursper
week), while body awareness and restorative training
were estimated to have an intensity of 2.5 METs (3.25
MET hours per week).
13
Safety
Pre-exercise screening was performed before high
intensity physical training. If one of the following cri-
teria was met, the participant was excluded from the
physical training component of the programme on
that specific day: diastolic blood pressure <45 mm
Hgor>95mmHg;pulseatrest>100beatsperminute;
temperature >38°C; respiration frequency >20 per
minute;infectionsrequiringtreatmentwithantibiotics;
ongoing bleeding; fresh petechiae; bruises; B throm-
bocytes <50×10
9/l; B leucocytes <1.0×10
9/l. During
the training sessions the participants’ heart rate was
continuously monitored by means of a wireless heart
rate transmitter, and the participants were advised to
respect their own physical limitations.
Control group
Participants assigned to the control group received
conventional medical care, and completed outcome
measures in parallel with the intervention group. The
control group was allowed to freely increase physical
activity. They were invited to participate in the exer-
cise programme after the six week assessments.
Primary and secondary outcome measures
Assessment included patient rated and objectively
measured physiological outcomes. All outcomes
were assessed at baseline and after intervention. The
primary outcome, fatigue, was assessed using the Eur-
opean Organization for Research and Treatment of
Cancer Quality of Life Questionnaire (EORTC
QLQ-C30; 30 items).
20 The EORTC QLQ-C30 com-
prises five functional scales, nine symptom scales or
items, and a global health status/quality of life scale.
All scale/single item measures range in score from 0-
100. A high score on the functional and global health
status/quality of life scale represents a high or healthy
level of functioning and high quality of life, while a
high score for a symptom scale represents a high level
Patients with cancer referred for chemotherapy during study period (n=1956)
Assessed for eligibility (n=953)
Agreed to attend pre-screening (n=506)
Randomised (n=269)
Allocated to control (n=134) Allocated to intervention (n=135)
Assessed at 6 weeks (n=117) Assessed at 6 weeks (n=118)
Declined to attend pre-screening (n=447):
  Not interested in exercise (n=226)
  Too far to travel (n=85)
  Too busy (n=112)
  Other reasons (n=24)
Did not meet inclusion criteria (n=237):
  Performance status >2 (n=44)
  Health problems (n=77)
  Chemotherapy completed (n=45)
  Other reasons (n=71)
Not assessed at 6 weeks (n=17):
  Not contactable (n= 3)
  Absent from test (n= 8)
  Infections (n=2)
  Bone marrow suppression (n=4)
Not assessed at 6 weeks (n=17):
  Never started programme (n=2)
  Infections (n=7)
  Bone marrow suppression (n=4)
  Excluded (n=1)
  Other health problems (n=3)
Fig 1 | Trial profile
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other scales on EORTC QLQ-C30, and general well-
beingwasfurtherassessedwiththeMedicalOutcomes
StudyShortForm(MOSSF-36),
21whichcontainseight
scalesmeasuringgeneralhealthconceptsandtwosum-
mary scales: physical component scale, and mental
component scale.
Leisure time physical activity level was explored by
questionnaire. The participants were classified as:
sedentary (completely inactive); walking or cycling
for pleasure; regular physical exercise at least 3 hours
aweek;orintensephysicalactivitymorethan4hoursa
week.
22-24
Other secondary outcomes included muscular
strength stated in kilograms and aerobic capacity
(Vo2max)statedinl/min.Muscularstrengthwasascer-
tained using the one repetition maximum test to eval-
uate upper and lower body strength.
25 The tests were
performed on Technogym (Gambettola, Italy) vari-
able resistance equipment (chest press, leg press, and
pull down) and targeted large muscular groups. Each
patient started the test with three to four repetitions on
each machine, on a low weight. The patient would
increase the weight by 2.5 kg continuously. The test
was complete when the patient reached maximum
capacity(onerepetitionmaximum).Toobtainanover-
all score for improvement in muscular strength we
used the mean of the relative changes in strength in
chest press, leg press, and pull down.
Vo2max was indirectly estimated by use of a step-
wise work capacity on a stationary exercise cycle
(Monark Ergomedic 839E, Sweden). The steady rate
test started with a workload of 67 W over 8 minutes
with the patients’ pulse rate being recorded during
the final minute of the test. The watt max test started
at 67 W, increasing by 20 W with each consecutive
minute until the patient did not wish to continue
cycling. Vo2max was estimated using the formula
Vo2max=0.16+(0.0117×MPO) where maximal power
out (MPO) was measured in watts.
26
To compare estimated Vo2max with the maximum
oxygen consumption both measurements were done
in seven patients, and no significant difference was
found between the tests.
27 We chose to use estimated
Vo2maxbecausethismethodwasfeasibleforuseinthe
study population.
Demographic and behavioural data were collected
by self report, and medical data were drawn from
records.
Sample size calculation and statistical analysis
According to the scoring manual for EORTC QLQ-
C30 a change of 10 points or more is considered to
be a moderate to large clinically significant change.
20
Based on this assumption and our pilot study (n=82)
28
the sample size was calculated on an 80% power to
detect a difference in score of 10 points (SD 25) on
the EORTC QLQ-30 fatigue scale (items 10,12, and
18), using a type 1 error of 5%, a type 2 error of 20%,
andunivariateanalysis(ttest).Thiscalculationresulted
in 98 participants in each group. To accommodate
expected dropout before study completion, because
of inclusion of participants with present evidence of
disease, a total of 135 participants were included in
each group.
Baseline comparisons were done using univariate
analysesofvarianceforcontinuousvariables.Forcate-
gorical measures likelihood ratio based χ
2test for sym-
metryandmarginalhomogeneitywasusedtoevaluate
the potential changes.
Control group (n=134) Intervention group (n=135)
Demographic characteristics
Age, years
Mean (SD) 47.2 (10.6) 47.2 (10.7)
Range 20-65 21-65
Married, cohabiting, or in a relationship 89 (66.9) 95 (70.4)
Sex
Male 39 (29.1) 34 (25.2)
Female 95 (70.9) 101 (74.8)
Completed secondary school or higher 106 (79.7) 104 (77.0)
Current smoker 19 (14.3) 26 (19.3)
Medical characteristics
Median (range) days since diagnosis 89.5 (31-271) 83 (34-280)
No evidence of disease (NED) baseline 72 (53.7) 68 (50.4)
Evidence of disease (ED) baseline 62 (46.3) 67 (49.6)
Relapsed disease 26 (19.4) 17 (12.6)
Mean (SD) β haemoglobin, mmol/l 7.90 (0.8) 7.95 (0.8)
Cancer of breast (NED/ED) 59 (50/9) 60 (49/11)
Cancer of bowel (NED/ED) 17 (10/7) 18 (13/5)
Oncological malignancies (NED/ED)
Cancer of ovaries 11 (3/8) 16 (5/11)
Cancer of testes 9 (0/9) 7 (0/7)
Cancer of oesophagus 3 (0/3) 2 (0/2)
Cancer of brain 4 (0/4) 1 (0/1)
Cancer of cervix 2 (0/2) 4 (0/4)
Cancer of pharynx 1 (0/1) 2 (0/2)
Cancer of pancreas 2 (0/2) 1 (0/1)
Cancer of stomach 2 (0/2) 1 (0/1)
Other diagnoses 9 (3/6) 10 (1/9)
Haematological malignancies (NED/ED) 15 (6/9) 13 (0/13)
Hodgkin’s4 6
Non-Hodgkin’s lymphoma 5 7
Acute leukaemia 5 0
Chronic leukaemia 1 0
Physical activity level
Pre-illness
Sedentary 5 (4.0) 10 (7.5)
Walking or cycling for pleasure 34 (27.0) 40 (30.1)
Regular physical exercise, at least 3 h/week 75 (59.5) 74 (55.6)
Intense physical activity, more than 4 h/week 12 (9.5) 9 (6.8)
Baseline
Sedentary 25 (19.8) 23 (17.4)
Walking or cycling for pleasure 48 (38.1) 75 (56.8)
Regular physical exercise, at least 3 h/week 47 (37.3) 30 (22.7)
Intense physical activity, more than 4 h/week 6 (4.8) 4 (3.0)
Table 1 Demographic and medical characteristics, and physical activity level for all patients and by group
assignment. Values are numbers (percentages) of patients unless stated otherwise
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outcome (mean differences) between baseline and six
weeks existed between the control and intervention
groups in all outcome measures (EORTC QLQ-C30,
MOSSF-36,Vo2max,andmuscularstrength).Weper-
formed a forward stepwise regression analysis using
differences in outcome between baseline and six
weeks(inalloutcomemeasures)asthedependentvari-
ableinagenerallinearmodel.Thestepwiseprocedure
began by identifying the covariate that was most
strongly related to the dependent variable. The next
strongest related covariate was then selected after con-
trolling for the first covariate, and so on. The variable
intervention/control was fixed and the following cov-
ariates were tested: sex, age, cohabitation, educational
level,baselineoutcomescore,relativechangeinβhae-
moglobin, Vo2max, one repetition maximum knee
extension, and the five disease related covariates—
diagnosis, evidence of disease, relapse of disease, and
chemotherapy cycles before and during the study per-
iod. Potential effect modifications (interactions) of the
five disease related covariates and their effect on the
estimated mean difference were also tested.
All analyses were tested with a significance level of
P<0.05 by using the intention to treat principle. Avail-
able data for participants with missing data were
included under the “missing at random” assumption.
Clinically important changes were estimated as
effect sizes using Cohen’s guidelines, whereby a
value of 0.2 denotes a small, 0.5 a medium, and 0.8 a
large effect size.
29-31 Effect size was calculated by the
meandifferencedividedbythepooledstandarddevia-
tion, the root mean square error estimated from the
general linear model.
Participants classified as lost to follow-up (n=34)
were compared with the study group (n=235) for base-
line demographic data using ordinary t test and
2 χ
2test
for homogeneity.
Datawere enteredinto ExcelusingMicrosoftOffice
2000 Professional for Windows XP and SAS (version
9.1.3) software for statistical analysis.
RESULTS
Participants
During the study period (March 2004 to March 2007),
1956 patients with cancer aged 18-65 years were
referred for chemotherapy (fig 1). Two hundred and
sixtyninepatientsmettheinclusioncriteriaandagreed
to participate. For the primary outcome (fatigue) we
obtained post-intervention data from 118 participants
in the intervention group (87.4%) and 117 in the con-
trol group (87.3%). The intervention group adherence
rate was 70.8% (17 of 24 training days, range 3-24) of
their supervised exercise sessions.
The control and intervention groups were matched
at baseline for demographic and medical characteris-
tics(table 1).Participantswereonaverage47yearsold
(range 20-65 years), and 73% were female. The study
included patients with 21 different cancer diagnoses:
17 with solid tumours and four with malignant haema-
tological diseases.Forty eightper cent had evidence of
disease and 52% no evidence of disease. The median
number of days since diagnosis was 84.
The participants received a total of 59 different che-
motherapy regimens during the study period. The
most frequent chemotherapy regimen included cyclo-
phosphamide, epirubicin, and 5-fluorouracil and was
administered to 49 patients in each group. Also fre-
quent were 5-fluorouracil based regimens in patients
with colorectal cancer (12 in the control group and 14
in the intervention group) and platinum based regi-
mens in women with ovarian cancer (10 v 15) and in
men with testicular cancer (eight v six). All other regi-
mens were given to fewer than five patients and regi-
menswerebalancedbetweengroups.Theintervention
and control groups had received a mean of 2.5 and 2.6
cycles of chemotherapy, respectively, before the study
period, and received a mean of 1.9 and 1.8 cycles,
respectively,duringthesixweekstudyperiod(table 2).
Main outcomes
Changes in patient rated outcomes
Tables 3and4presentthepatientratedoutcomesmea-
sured at baseline and after six weeks for the inter-
vention and the control groups.
We found a significant effect in favour of the inter-
vention group for the primary outcome, fatigue, in
EORTC QLQ-C30. The fatigue score was reduced in
the intervention group by an estimated mean differ-
ence of −6.6 points (95% CI −12.3 to −0.9) compared
with the control group (P=0.02, effect size=0.33, 95%
CI 0.04 to 0.61) (table 3).
Table 2 |Chemotherapy cycles and surgery, by group
assignment. Values are numbers of patients unless stated
otherwise
Control group
(n=134)
Intervention
group (n=135) P value
Chemotherapy
cycles
Before study period —— 0.75
1 cycle 33 41
2 cycles 43 37
3 cycles 25 21
4 cycles 16 19
>4 cycles 17 17
Mean 2.6 2.5
During study period —— 0.37
1 cycle 29 39
2 cycles 96 89
>2 cycles 9 7
Mean 1.8 1.9
Advanced/adjuvant 72/62 73/62
Surgery 109 109
Mastectomy 39 33
Lumpectomy 19 25
Hysterectomy 11 16
Ileo-colostomy 5 3
Orchiectomy 8 6
Other 27 26
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seven of 10 subscales on general wellbeing (MOS
SF-36): physical functioning (effect size 0.37, 95% CI
0.09 to 0.65), role physical (0.37, 0.10 to 0.64), vitality
(0.55, 0.27 to 0.82) role emotional (0.32, 0.05 to 0.59),
mentalhealth (0.28,0.02 to0.56), physicalcomponent
scale (0.35, 0.06 to 0.63), and mental component scale
(0.41,0.14to0.69)(table 4).Significantinteractionwas
seen for role physical, with greater improvement in
patients with no evidence of disease than in those
with evidence of disease.
Changes in objectively measured physiological outcomes
Vo2maxincreasedmoreintheinterventiongroupthan
in the control group (table 5); the mean improvement
in Vo2max was 10.7% (SD 0.5) compared with no
changeinthecontrolgroup.Significantimprovements
in muscular strength were seen in favour of the inter-
ventiongroup.Theaverageimprovementinmuscular
strength was 29.6% (SD 36.4) for the intervention
group (table 5). Significant interaction was seen for
the muscular strength chest press, with more improve-
ment in patients with no evidence of disease than in
those with evidence of disease.
Changes in self reported physical activity level
Sixty-six per cent of the study population reported
physical activity of at least 3 hours per week before
their illness, whereas at baseline 18% had a sedentary
lifestyle, when undergoing chemotherapy (table 1);
only 33% of the population reported physical activity
of at least 3 hours per week. Homogeneity of the mar-
ginaldistributionwasnotfulfilled(P<0.0001);thelevel
of self reported physical activity fell during the period
from pre-illness to baseline for both the intervention
and control group.
Inthecontrolgroupthejointdistributionofbaseline
and post intervention physical activity satisfied sym-
metry(P=0.4)andassuchhomogeneityofthemarginal
distribution, indicating that the level of physical activ-
ity level had not changed during the period. By con-
trast,neitherthe hypothesisofsymmetrynormarginal
homogeneity was fulfilled (P<0.0001 for both hypoth-
eses) for the intervention group. Post intervention, the
patients increased their activity level. The mode chan-
ged from “walking or cycling for pleasure” (40%) at
baselineto”regularphysicalexercise”(53%)afterinter-
vention.
DISCUSSION
Principal findings
Men and women with a broad range of ages, cancer
diagnoses, disease statuses, and chemotherapy regi-
mens participated in this study. The multimodal inter-
vention of high intensity exercise, relaxation, body
awareness training, and massage for patients under-
going chemotherapy showed broad effects. We noted
significanteffectsonfatigue,vitality,physicalfunction-
ing, role functioning, role emotional, mental health,
physical component scale, and mental component
scale, physical capacity (Vo2max and muscular
strength), and physical activity levels, while global
health status/quality of life and symptom scales did
not show improvements.
Table 3 |Health related Quality of Life (EORTC QLQ-C30) outcome variables and estimated
differences P values (adjusted general linear model)
Outcome variable
Mean (SD) Test (reference: control)
Baseline 6 weeks
Estimated mean difference
(95% CI) P*
Maximum number
Control 134 117 NA NA
Intervention 135 118 NA NA
Globalhealthstatus/qualityoflife
Control 60.2 (22.4) 63.3 (22.4)
Intervention 63.8 (21.1) 67.2 (20.3) 2.2 (−2.7 to 7.1) 0.4
Physical functioning
Control 84.0 (15.7) 86.4 (14.5)
Intervention 84.7 (14.5) 89.0 (12.4) 2.4 (−0.4 to 5.1) 0.09
Role functioning
Control 65.6 (28.5) 68.9 (26.5)
Intervention 68.7 (28.4) 74.8 (26.3) 4.6 (−1.7 to 10.9) 0.2
Emotional functioning
Control 75.7 (19.3) 80.6 (17.8)
Intervention 77.6 (12.2) 81.3 (17.2) −0.3 (−4.0 to 3.4) 0.9
Cognitive functioning
Control 81.9 (17.8) 81.3 (19.8)
Intervention 84.4 (17.1) 83.8 (16.7) 1.7 (−2.6 to 6.0) 0.4
Social functioning
Control 78.6 (21.2) 79.4 (20.8)
Intervention 83.3 (20.6) 82.6 (20.5) 4.5 (−1.4 to 10.3) 0.1
Fatigue
Control 43.0 (23.9) 41.0 (22.7)
Intervention 39.7 (25.8) 34.6 (24.3) −6.6 (−12.3 to −0.9) 0.02
Nausea and vomiting
Control 17.3 (21.7) 13.7 (18.4)
Intervention 16.0 (22.9) 13.4 (17.3) −0.6 (−5.2 to 3.9) 0.8
Pain
Control 15.4 (22.7) 16.8 (20.6)
Intervention 17.4 (22.4) 14.6 (17.1) −2.9 (−7.6 to 1.7) 0.2
Dyspnoea
Control 18.2 (25.3) 18.2 (24.4)
Intervention 15.3 (21.6) 14.3 (21.5) −2.9 (−8.6 to 2.7) 0.3
Insomnia
Control 32.7 (31.5) 26.4 (27.5)
Intervention 22.7 (26.9) 18.4 (23.9) −3.5 (−9.5 to 2.6) 0.3
Appetite loss
Control 16.5 (26.6) 14.6 (22.1)
Intervention 18.4 (27.6) 12.8 (22.3) −3.4 (−8.9 to 2.0) 0.2
Constipation
Control 22.2 (29.5) 18.4 (25.3)
Intervention 16.7 (24.0) 20.8 (39.4) 4.5 (−4.0 to 13.1) 0.3
Diarrhoea
Control 14.0 (23.5) 13.0 (21.9)
Intervention 14.8 (28.0) 17.0 (26.1) 4.1 (−1.7 to 10.0) 0.2
Financial difficulties
Control 14.3 (27.7) 13.0 (25.9)
Intervention 11.1 (21.5) 10.8 (19.3) −0.3 (−5.0 to 4.4) 0.9
*Adjusted general linear model.
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mustbeviewedasanentity,wherebyeachcomponent
hashadaroleintheoutcomes.Ourfindingsconfirmed
that both men and women benefited from training in
mixed groups, and no differences between men and
women were observed in the dropout rate.
The primary outcome, fatigue, was the most fre-
quently reported symptom; 65% of the study popula-
tion reported a fatigue level greater than that of the
general population (mean >20) at baseline
31 and 29%
reported severe fatigue (mean >60).
The effect size of the improvement in fatigue (0.33)
suggests a small to medium clinically important
change.
293032 Our result differs from findings of a
meta-analysis which indicated that the magnitude of
effect from exercise on cancer related fatigue might
be too small to be clinically meaningful (effect
size=0.13, 95% CI −0.06 to 0.33).
7 A Cochrane meta-
analysis found the association between exercise and
fatigue to be insignificant and inconclusive owing to
lack of studies.
9 Likewise, two recent exercise studies
of moderate intensity in women with breast cancer
receiving adjuvant chemotherapy found no significant
improvements in fatigue.
3334
The cause of fatigue in cancer patients remains neb-
ulous and multifactorial. Patients report fatigue as a
state of physical disturbance and loss of function, with
exhaustion being the lead factor in reduced physical
activity. Severe fatigue results from extreme muscular
de-conditioning caused by both the disease and treat-
ment but can also be triggered by a sedentary
lifestyle.
35 However, only 18% of the study population
had a sedentary lifestyle at baseline, which may indi-
cate that their fatigue burden was primarily due to the
disease or to the chemotherapy. The patients’ level of
fatigue (mean 39.7, SD 25.8) corresponded to those
obtained in other studies investigating cancer patients
with the same WHO performance status and severity
of disease (mean 40, SD 26).
32
Although the intervention reduced the patients’
levels of fatigue after six weeks (mean 34.6, SD 24.3)
the scores after intervention did not reach the level of
the general population (mean 21).
Our qualitative research with participants from the
pilotstudyshowedthatareductioninfatiguecouldnot
be interpreted as an overall improvement in quality of
life. However, a complete, partial, or periodic reduc-
tion in fatigue affected the patients’ daily lives.
36
Consistentwithrecentlypublishedstudiesandmeta-
analyses on exercise interventions, including those in
women receiving adjuvant therapy for breast
cancer
7-93334 we found no significant improvements in
global health status/quality of life (EORTC QLQ-
C30), which incorporates two questions: “How would
yourateyouroverallhealthduringthepastweek?”and
“Howwouldyourateyouroverallqualityoflifeduring
the past week?”
Courneyaetal testedresistanceversusaerobic exer-
cise for the duration of the patients’ chemotherapy (
17 weeks) in 242 patients with breast cancer. Neither
aerobic exercise nor resistance training significantly
improved cancer specific quality of life (as measured
by functional assessment of cancer therapy
questionnaire—anaemia).
34 Mutrie et al conducted a
12weeksupervisedgroupexerciseprogrammeduring
chemotherapy for early stage breast cancer in 203
women, and no significant effect was seen for general
quality of life (functional assessment of cancer therapy
questionnaire—general).
33
The failure of the intervention to significantly
improve global health status/quality of life indicates
that this type of short term intervention was not able
to overcome the complexity of patients’ overall nega-
tively affected situation. Being diagnosed with cancer
and exposed to chemotherapy disrupts the patient’s
life, affecting physiological and psychological func-
tioning and contributing to negative effects on the glo-
bal health status/quality of life.
3738 Improvements in
this measure may have been too ambitious a goal in
this short term clinical trial.
Table 4 |General wellbeing (MOS SF-36) outcome variables and estimated differences
Outcome variable
Mean (SD) Test (reference: control)
Baseline 6 weeks
Estimated mean difference
(95% CI) P*
Maximum number
Control 134 117 NA NA
Intervention 135 118 NA NA
Physical functioning
Control 83.6 (14.8) 84.3 (16.2)
Intervention 84.3 (13.7) 88.2 (13.2) 4.4 (1.1 to 7.7) 0.01
Role physical
Control 27.1 (35.7) 31.8 (37.6)
Intervention 30.5 (35.2) 46.1 (40.2) 12.4 (3.4 to 21.5) 0.007
Bodily pain
Control 74.0 (24.6) 75.7 (22.7)
Intervention 70.9 (27.6) 77.6 (20.0) 3.4 (−1.2 to 8.0) 0.2
General health perceptions
Control 61.1 (22.9) 65.5 (22.4)
Intervention 64.9 (18.4) 68.7 (19.7) 0.6 (−3.7 to 4.9) 0.8
Vitality
Control 55.8 (21.1) 55.6 (21.6)
Intervention 57.8 (20.2) 65.5 (18.1) 8.8 (4.4 to 13.1) <0.0001
Social functioning
Control 75.4 (21.8) 76.5 (22.0)
Intervention 77.0 (21.1) 79.7 (22.2) 2.4 (−2.8 to 7.6) 0.4
Role emotional
Control 58.6 (41.2) 58.7 (41.9)
Intervention 56.1 (39.0) 69.6 (40.1) 12.0 (1.9 to 22.0) 0.02
Mental health
Control 72.0 (16.7) 74.2 (16.1)
Intervention 74.0 (16.3) 78.6 (15.0) 3.3 (0.2 to 6.4) 0.04
Physical component scale
Control 44.3 (8.3) 45.1 (8.5)
Intervention 44.2 (8.4) 47.4 (6.7) 1.9 (0.3 to 3.4) 0.02
Mental component scale
Control 46.9 (10.2) 47.3 (10.0)
Intervention 46.5 (9.7) 50.5 (9.4) 3.2 (1.1 to 5.4) 0.004
*Adjusted general linear model.
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seven of eight somatic symptom scales in the
EORTC QLQ-C30 questionnaire. This finding might
because many side effects induced by chemotherapy
can be prevented or treated by supportive care drugs;
for example, evidence based guidelines exist for the
prevention and treatment of nausea, vomiting, and
diarrhoea.
39
Supportive medical treatment may consequently
have caused the observed floor effect where 50-70%
ofthestudypopulationwereplacedinthelowestquar-
tilesonsixofthesymptomscales.Similarlywefounda
ceiling effect on three EORTC QLQ-C-30 functional
scales.
By contrast, no such floor-ceiling effect was seen
when applying the general wellbeing MOS SF-36
scale—which might be a more sensitive tool than the
others for measuring effects of exercise in cancer
patients—a finding confirmed in other exercise inter-
vention studies.
1140
Significant effects of the intervention were recorded
for seven of 10 subscales for general wellbeing (MOS
SF-36), with small to medium effect sizes for six of the
scales. The present multimodal intervention showed
greater significant effects and higher mean differences
on several scales (MOS SF-36) compared to a 26 week
supervised aerobic exercise programme in breast can-
cer patients receiving less toxic chemotherapy.
40 Parti-
cularly, vitality showed an effect size that was greater
than medium (0.55). In existing meta-analyses regard-
ing exercise based interventions, fatigue and quality of
life are often highlighted, while measurement of vital-
ityanditsassociationwithfatiguearenot.
7-9Inthepre-
sentstudyanexplorativegenerallinearmodelanalysis
demonstrated that changes in fatigue were strongly
affected by an increase in vitality. This finding may
suggest that the multimodal intervention including a
high intensity component generates vitality and
thereby reduces fatigue. The patients’ perception of
improved vitality is important especially during che-
motherapy treatment periods.
36
At baseline, the patients had a mean score of 30.5
(SD 35.2) on the role physical scale, which was below
that of the general Danish population range (mean
83.1, SD 31.7).
41 By comparison with the control
group the intervention group showed a lesser degree
oflimitationby theirphysicalstatuswhen carryingout
daily activities after intervention. Overall, they are
ranked at a considerably lower level than the general
population. By contrast, the patients in the inter-
vention group scored high on the physical functioning
scale at baseline (mean 84.3, SD 37.2) and after the six
week intervention (mean 88.2, SD 13.2), their score
was similar to that of the general Danish population
(mean 87.6, SD 19.4).
41 This finding confirms possibly
the patient group’s predisposition for doing physical
activity and that the intervention group was prepared
to partake in demanding activities without health
relatedconstraints.With respect tothe role emotional,
mental health scales, and mental component scale, the
patients in the intervention group showed significant
improvement but had lower scores than their age
equivalents in the general population.
In summary, our results in patient rated outcomes
show small to medium effect sizes across a broad spec-
trum of physical and emotional wellbeing scales,
including vitality and self reported physical activity
levels. Furthermore, we found a reduction in fatigue,
which we consider to be of importance to the patients’
daily lives, even though nochange wasseen in the glo-
bal health status/quality of life.
Objectively measured physiological outcomes also
showed significant improvement in aerobic capacity
and muscular strength. Studies in healthy adults and
in people with cardiac and renal illnessesand with dia-
beteshaveshownthatcombinedresistanceandcardio-
vascular training programmes can have a range of
beneficial effects such as increased physical function,
aerobic capacity, and reduced muscular fatigue.
42-46
Similarly, the results of the present study confirm that
patients with cancer, even those undergoing
Table 4 |General wellbeing (MOS SF-36) outcome variables and estimated differences
Outcome variable
Mean (SD) Test (reference: control)
Baseline 6 weeks
Estimated mean difference
(95% CI) P*
Maximum number
Control 134 117 NA NA
Intervention 135 118 NA NA
Physical functioning
Control 83.6 (14.8) 84.3 (16.2)
Intervention 84.3 (13.7) 88.2 (13.2) 4.4 (1.1 to 7.7) 0.01
Role physical
Control 27.1 (35.7) 31.8 (37.6)
Intervention 30.5 (35.2) 46.1 (40.2) 12.4 (3.4 to 21.5) 0.007
Bodily pain
Control 74.0 (24.6) 75.7 (22.7)
Intervention 70.9 (27.6) 77.6 (20.0) 3.4 (−1.2 to 8.0) 0.2
General health perceptions
Control 61.1 (22.9) 65.5 (22.4)
Intervention 64.9 (18.4) 68.7 (19.7) 0.6 (−3.7 to 4.9) 0.8
Vitality
Control 55.8 (21.1) 55.6 (21.6)
Intervention 57.8 (20.2) 65.5 (18.1) 8.8 (4.4 to 13.1) <0.0001
Social functioning
Control 75.4 (21.8) 76.5 (22.0)
Intervention 77.0 (21.1) 79.7 (22.2) 2.4 (−2.8 to 7.6) 0.4
Role emotional
Control 58.6 (41.2) 58.7 (41.9)
Intervention 56.1 (39.0) 69.6 (40.1) 12.0 (1.9 to 22.0) 0.02
Mental health
Control 72.0 (16.7) 74.2 (16.1)
Intervention 74.0 (16.3) 78.6 (15.0) 3.3 (0.2 to 6.4) 0.04
Physical component scale
Control 44.3 (8.3) 45.1 (8.5)
Intervention 44.2 (8.4) 47.4 (6.7) 1.9 (0.3 to 3.4) 0.02
Mental component scale
Control 46.9 (10.2) 47.3 (10.0)
Intervention 46.5 (9.7) 50.5 (9.4) 3.2 (1.1 to 5.4) 0.004
*Adjusted general linear model.
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bined resistance and cardiovascular training pro-
grammes.
According to a review of 26 studies by Galvao and
Newton,thepresentstudyisthefirstofitskindtoincor-
porate a high intensity design.
47 The results indicate
that the high intensity design is an effective training
programmeasbothmusclestrengthandoverallfitness
improvedduringashorttimeperiod.Patientswithevi-
dence of disease experienced the same improvement
as patients with no evidence of disease. Improvements
in muscle strength and fitness in this intervention are
within the same range as in the exercise interventions
that included patients with lesser burden of disease
post-treatment and who showed improvement in spe-
cific areas despite longer training periods. The dura-
tion and frequency of the high intensity training
sessions in the present study (270 minutes per week)
imply a larger training volume than in single mode
exercise interventions (120-135 minutes per
week).
7947
Improvement in the patients’ self reported vitality
and physical functioning were probably attributable
to the high intensity component, since a connection
exists between high intensity training and vitality in
healthy athletes.
48
On days with high intensity exercise training, the
sessions closed with low intensity relaxation training.
The aim was to assist the patients to recognise and test
their own physical reactions, such as dizziness, over-
exertion, and cold sweat. The patients were advised
to concentrate on breathing and muscle tension, and
gain awareness of their physical and mental reactions.
In this way the patients stabilised physically and emo-
tionallybeforereturningtotheirdailyactivities.These
findings correspond to single intervention studies
regarding patients’ perception of self control.
49 On
the other hand the intervention did not affect the
patients’ levels of nausea, vomiting and pain suggest-
ing non-effectiveness or simply that the patients in this
study had a low level of symptoms at baseline.
Incorporating a heterogeneous group of cancer
patients, each presenting different treatment related
side effects, increases the need for daily pre-exercise
screening by clinical nurse specialists. This has been
of importance in preventing serious adverse events
during high intensity programmes. Five participants
wereexcludedfromthehighintensityphysicaltraining
component (total of 25 times) during the study period
because of leucopenia and/or increased blood pres-
sure. Intermittent increase in heart rate and/or blood
pressure were commonly observed in two or three
patients weekly. In these cases, values for heart rate
and blood pressure were retained after 10 minutes of
recline, to meet pre-screening criteria and approval to
enter the exercise room.
Five participants with breast cancer had lympho-
edema at baseline; none experienced exacerbations
during the intervention. One participant with a brain
tumour experienced a grade 3 seizure after cardio-
vascular training. This participant was admitted to the
hospital,recoveredwithin3hours,andwasdischarged
the same day. The participant was subsequently
excluded from the intervention. We must therefore
advise patients with brain tumours or brain metastases
not to participate in high intensity exercise inter-
ventions. The inclusion and exclusion criteria, the
dailyscreeningprocedures,thepresenceoftheclinical
nursespecialistduringtraining,andtrainingsphygmo-
manometer ensured the required level of safety. The
combination of a training facility at the hospital and
professional supervision was crucial and confirmed
the patients’ understanding that the training pro-
gramme was a supplement to medical treatment.
Despite the multimodal intervention being short term
(sixweeks)thevolumeoftheinterventionseemedade-
quate.
Strengths and weaknesses
Thetrialhadalargesamplesizeandincludedmaleand
female patients with advanced cancer and different
types of diagnoses. The strengths of the trial include
supervised and structured exercise, combined high
and low intensity components, use of validated objec-
tive physiological measurements, validated question-
naires, intention to treat analyses, and limited
dropout rate of 12.7%. All participants were under-
going chemotherapy during the study period. Limita-
tions included adherence rate of 70.8% and a 53%
recruitment rate, which are comparable with other
exercise interventions including cancer patients with
lesser disease burden.
3334
Oneweaknessofthestudyisthatwhilewewereable
to report the immediate effects of the intervention it
was not possible to perform valid comparisons of the
effect between the control and the intervention groups
3monthsafterintervention.Thereasonisthat59.7%of
the controlgroup patientssubsequently elected topar-
ticipate in the intervention following their six week
participation in the study. Study allocation was not
concealed, either to the patient or to the healthcare
professionals, and the control group was allowed to
freely increase physical activity.
Another weakness of the study is that the profes-
sionals conducting the daily exercise sessions also col-
lected the data, which may have led to significant bias.
However, research assistants who were not involved
with the participants keyed in and analysed the data.
Selfselectionofparticipantsinourstudyresultedina
sample of cancer patients who were overtly motivated
to engage in group based physical activity.
Our findings suggest that population heterogeneity
doesnotprecludeuseofthistypeofintervention.How-
ever,generalisationmaybelimitedbythewillingnessof
patients to allocate the necessary time to physical activ-
ity. Furthermore, all patients in the present study had a
good performance status (WHO 0-1) and did not have
brainorbonemetastases.Ourinterventionmayneedto
bemodifiedinpatientswithaperformancestatusof2or
greater.Finally,weconsideritagreatchallengetomoti-
vate patients whoare not interested in physical training
in groups with mixed gender.
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There is a considerable rationale for promoting multi-
modal exercise interventions to improve physical
capacity, vitality, and physical and mental wellbeing,
and to relieve fatigue during chemotherapy; thereby
supporting cancer patients’ daily living activities. The
range of exercise components used, from high inten-
sityactivitytorelaxation,bodyawarenesstraining,and
massage has been shown to be feasible, safe, and ben-
eficial to various patients with cancer during che-
motherapy, even patients with advanced disease.
Very few exercise interventions include cancer
patients with advanced disease and most of these
involve patients with haematological disease during
or after high dose chemotherapy and peripheral
blood stem cell transplantation.
5051 Patients with
advanced solid cancers differ substantially from these
patients—thus investigations including such patients
arestillneeded.Thepresentstudyhadaclearmajority
offemalepatients(73%).However,thenumberofpeo-
plewithcancereachyearisevenlydistributedbetween
the two sexes.
52-56 We thereforerecommendthatinter-
ventions should be developed with greater appeal to
male patients.
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